Late Recurrence Following Early Breast Cancer

Article Oncology

Mortality After Late Breast Cancer Recurrence in Denmark

Rikke Norgaard Pedersen et al.

Summary: Patients with late breast cancer recurrence have a more favorable prognosis compared to those with early recurrence, and the localization of recurrent disease is the main prognostic factor for breast cancer death.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

Rikke Norgaard Pedersen et al.

Summary: Research shows that there is still a risk of breast cancer recurrence up to 32 years after the initial diagnosis. Tumor size larger than 20 mm, lymph node-positive disease, and estrogen receptor-positive tumors are associated with increased risk of late breast cancer recurrence. Women with these characteristics may require extended surveillance, more aggressive treatment, or new therapy approaches.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

添加到收藏夹

Article Oncology

Clinical management and biology of tumor dormancy in breast cancer

Stefan Werner et al.

Summary: Clinical tumor dormancy refers to the extended latency period between removal of the primary tumor and subsequent relapse in cancer patients, particularly in breast cancer patients. Recent studies have shown that minimal residual disease in breast cancer patients can be monitored using liquid biopsy approaches. Although the biological principles underlying tumor dormancy in breast cancer patients are largely unknown, emerging mechanisms that control tumor dormancy have been identified.

SEMINARS IN CANCER BIOLOGY (2022)

添加到收藏夹

Review Oncology

Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches

David W. Cescon et al.

Summary: While the majority of breast cancers are diagnosed at a curable stage, approximately 20% of women will experience recurrence at a distant site during their lifetime. These metastatic recurrences are incurable with current therapeutic approaches. Numerous technologies are now available to detect minimal residual disease (MRD) after breast cancer treatment, but it is yet unknown how to best target and eradicate these cells. Clinical trials to test this hypothesis are challenging due to the rare nature of MRD in the blood and bone marrow, resulting in the need to screen a large number of survivors to identify those for study.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy

Iris Noordhoek et al.

Summary: This study found that BCI (H/I) as a biomarker could predict the benefit of extended endocrine therapy in patients with early-stage HR+ breast cancer, providing important clinical implications for treatment decisions.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology